Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.

Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, Xu X.

J Mol Diagn. 2014 Sep;16(5):558-63. doi: 10.1016/j.jmoldx.2014.04.008. Epub 2014 Jun 30.

PMID:
24994671
2.

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.

Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.

J Neurooncol. 2014 Nov;120(2):423-30. doi: 10.1007/s11060-014-1570-7. Epub 2014 Aug 7.

3.

Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.

Hsiao SH, Lin HC, Chou YT, Lin SE, Kuo CC, Yu MC, Chung CL.

Lung Cancer. 2013 Sep;81(3):455-61. doi: 10.1016/j.lungcan.2013.06.004. Epub 2013 Jul 18.

PMID:
23871711
4.

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K, Iizasa T.

Lung Cancer. 2013 Nov;82(2):282-7. doi: 10.1016/j.lungcan.2013.08.016. Epub 2013 Aug 28.

PMID:
24021541
5.

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.

Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.

Lung Cancer. 2014 Aug;85(2):161-7. doi: 10.1016/j.lungcan.2014.04.009. Epub 2014 Apr 29.

PMID:
24857785
6.

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Chen Y, Yang J, Li X, Hao D, Wu X, Yang Y, He C, Wang W, Wang J.

Cancer Sci. 2016 Dec;107(12):1800-1805. doi: 10.1111/cas.13079. Epub 2016 Nov 25.

7.

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.

Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.

PMID:
24629638
8.
9.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
10.

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.

Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1691-700. doi: 10.1007/s00432-013-1495-0. Epub 2013 Aug 22.

PMID:
23974272
11.

Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.

Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L.

Pathol Oncol Res. 2014 Apr;20(2):445-51. doi: 10.1007/s12253-013-9715-0. Epub 2013 Dec 3.

PMID:
24297623
12.

Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays.

Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, Chuang YT, Lin KY, Tsai CM, Chou TY.

J Thorac Oncol. 2014 Jan;9(1):91-6. doi: 10.1097/JTO.0000000000000041.

13.

Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.

Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y, Xiangqun S.

Med Oncol. 2014 May;31(5):926. doi: 10.1007/s12032-014-0926-3. Epub 2014 Apr 20.

PMID:
24748405
14.

Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.

Li H, Cao J, Zhang X, Song X, Wang W, Jia S, Li Z, Jia H, Cao X, Zhou W, Lian J, Han S, Yang W, Xi Y, Lian S, Jing H.

Clin Exp Metastasis. 2017 Jan;34(1):63-71. doi: 10.1007/s10585-016-9822-x. Epub 2016 Nov 25.

PMID:
27888377
15.

Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.

Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y, Li W, Li L, Liu X, Zheng B, Lu N, Ying J.

Lung Cancer. 2015 Sep;89(3):337-42. doi: 10.1016/j.lungcan.2015.06.008. Epub 2015 Jun 19.

PMID:
26141217
16.

Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC.

Oncologist. 2008 Dec;13(12):1276-84. doi: 10.1634/theoncologist.2008-0093. Epub 2008 Dec 5.

17.

Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.

Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, Iuchi T, Yokoi S, Kimura H, Iizasa T.

J Thorac Oncol. 2011 Jul;6(7):1215-20. doi: 10.1097/JTO.0b013e318219aaae.

18.

Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.

Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A.

Clin Cancer Res. 2015 Feb 1;21(3):642-51. doi: 10.1158/1078-0432.CCR-14-0846. Epub 2014 Nov 11.

19.

The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.

Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H.

Lung Cancer. 2011 Jul;73(1):45-50. doi: 10.1016/j.lungcan.2010.11.003. Epub 2010 Dec 3.

PMID:
21129809
20.

Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.

Seo AN, Park TI, Jin Y, Sun PL, Kim H, Chang H, Chung JH.

Lung Cancer. 2014 Mar;83(3):316-23. doi: 10.1016/j.lungcan.2013.12.008. Epub 2013 Dec 24.

PMID:
24412618

Supplemental Content

Support Center